Crispr Therapeutics AG (CRSP)

[jondoeuk]

''Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum -89%), a mean reduction in triglycerides (TG) of -55% (maximum -84%), and a mean reduction of low-density lipoprotein (LDL) of -49% (maximum -87%) at the highest dose-

Among participants with elevated baseline TG (>150 mg/dL), a mean reduction of 60% in TG were observed at therapeutic doses

CTX310 was well tolerated with no treatment-related serious adverse events and no ≥Grade 3 changes in liver transaminases''

https://uk.finance.yahoo.com/news/crispr-therapeutics-announces-positive-phase-145600051.html

Slides https://ir.crisprtx.com/static-files/71bae76f-e18f-4b2a-bafd-86c5a774f20d

NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2511778